Autologous Matrix-induced Chondrogenesis Market Size

Autologous Matrix-induced Chondrogenesis Market Analysis

The autologous matrix-induced chondrogenesis market studied is expected to register a CAGR of 8.1% during the forecast period.

• COVID-19 severely impacted the autologous matrix-induced chondrogenesis market, as many orthopedic surgeries were canceled or delayed to reduce the spread of infection during the early period of the pandemic. For instance, an article published in the Medicine journal in September 2022 revealed that authorities in many countries postponed hip and knee replacement surgeries to prevent the virus from spreading. In the United States, this resulted in the cancellation of 33 thousand primary hip and knee replacements every week until 2020, with roughly 130 thousand surgeries rescheduled. As a result, COVID-19 had a significant impact on the autologous matrix-induced chondrogenesis market. However, with the resumption of operations and a decrease in COVID-19 instances, the market is predicted to recover from the COVID-19 reduction over the forecast period.
• The rising prevalence of bone and joint disorders, increasing sports and other injuries, and growing demand for minimally invasive procedures are some of the factors driving market growth. Knee and hip replacement surgeries have increased globally in recent years, with persistent wound drainage being a well-known complication that commonly leads to wound development. The increase in surgical procedures is expected to drive demand for the autologous matrix-induced chondrogenesis market. For example, as per the June 2022 report of the Canadian Institute of Health Information, approximately 110 thousand joint replacements were performed in 2020-2021, and more than 7.3 thousand were performed as day surgery, representing a four-fold increase from the previous year, which is expected to drive the growth of the market segment.
• Furthermore, research studies demonstrating the advantages offered by autologous matrix-induced chondrogenesis are likely to increase opportunities for market growth. For instance, an article published in June 2022 in PubMed revealed that AMIC is useful for treating focal chondral abnormalities in the knee. Moreover, AMIC demonstrated a higher International Knee Documentation Committee (IKDC), a lower visual analog scale (VAS) value, and a lower rate of revision compared to microfracture (MFx). Similarly, an article published in November 2022 in PubMed revealed that according to the main findings of the study, the AMIC technique could be effective in improving symptoms and function in patients with osteochondral lesions (OCLs) of the talus. Statistically significant decreases in pain and enhancements of ankle function (AOFAS/FFI) were observed. Thus, such research studies demonstrate the advantages offered by autologous matrix-induced chondrogenesis and are likely to fuel market growth.
• However, the lack of a proper reimbursement system and the scarcity of skilled professionals are expected to hinder market growth. Overall, due to the rise in the prevalence of bone and joint disorders and the increase in research studies depicting the advantages of autologous matrix-induced chondrogenesis, the studied market is likely to witness notable growth over the forecast period.